NeuroScientific Biopharmaceuticals Limited (NSB.AX)
- Previous Close
0.0520 - Open
0.0510 - Bid 0.0480 x 15830000
- Ask 0.0500 x 11021100
- Day's Range
0.0480 - 0.0510 - 52 Week Range
0.0350 - 0.1400 - Volume
377,703 - Avg. Volume
728,364 - Market Cap (intraday)
6.941M - Beta (5Y Monthly) 0.49
- PE Ratio (TTM)
4.80 - EPS (TTM)
0.0100 - Earnings Date Jul 26, 2024 - Jul 30, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
NeuroScientific Biopharmaceuticals Limited develops therapeutic treatments for neurodegenerative diseases through preclinical and clinical studies of patented technologies. The company's lead drug candidates include EmtinB for treatment of neurodegenerative dementia and Alzheimer's disease, and degenerative conditions of the optic nerve. It was incorporated in 2002 and is based in Cottesloe, Australia.
www.neuroscientific.comRelated News
Performance Overview: NSB.AX
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NSB.AX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NSB.AX
Valuation Measures
Market Cap
6.94M
Enterprise Value
3.60M
Trailing P/E
8.89
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.82
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
4.00
Financial Highlights
Profitability and Income Statement
Profit Margin
20.06%
Return on Assets (ttm)
10.22%
Return on Equity (ttm)
23.29%
Revenue (ttm)
3.79M
Net Income Avi to Common (ttm)
761.17k
Diluted EPS (ttm)
0.0100
Balance Sheet and Cash Flow
Total Cash (mrq)
3.34M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-405.58k
Company Insights: NSB.AX
NSB.AX does not have Company Insights